Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

• Ages 18 years and older
• All sexes
• Adult, Older adult

Study population: The study population will consist of adults diagnosed with obstructive hypertrophic cardiomyopathy (oHCM) who initiate mavacamten treatment at medical institutions in Japan

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

About this study

Official title: Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy (oHCM) in Japan

Conditions

Obstructive Hypertrophic Cardiomyopathy (oHCM)

Being tested

Mavacamten

Keywords

Obstructive hypertrophic cardiomyopathy (oHCM)

Medical subject headings

Cardiomyopathy, Hypertrophic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

• MavacamtenDrug

  According to the product label

What is being measured

The primary outcome is the main question the study is designed to answer.

1. Incidence of adverse events (AEs) and/or serious AEs (SAEs)

   Measured: Up to 52 weeks

2. Actions taken after adverse events (AEs) and/or serious AEs (SAEs)

   Measured: Up to 52 weeks

3. Outcome of adverse events (AEs) and/or serious AEs (SAEs)

   Measured: Up to 52 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1. First posted3 Feb 2026
2. Study start21 May 2025
3. Primary completion30 Nov 2029 (estimated)
4. Study completion30 Nov 2029 (estimated)

Resources

• Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
• Other trials for Obstructive Hypertrophic Cardiomyopathy (oHCM)Studies of the same condition, open and under way.
• More trials run by Bristol-Myers SquibbThe sponsor's other registered studies.
• What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.